---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical gene therapy"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical gene therapy. Topics: Guideline description: nadofaragene firadenovec, Nadofaragene firadenovec: labeled indication, Nadofaragene firadenovec: dosing and administration, Nadofaragene firadenovec: efficacy in the pivotal trial (label), and 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/intravesical-gene-therapy"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical gene therapy

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Intravesical Gene Therapy

<a id="topic-2.2.2.1.3-1"></a>

### Guideline description: nadofaragene firadenovec

> “Nadofaragene firadenovec (rAd-IFNα/Syn3) consists of rAd-IFNα, a non-replicating recombinant adenovirus vector-based gene therapy that delivers a copy of the human interferon alfa-2b gene to urothelial cells, and Syn3, a polyamide surfactant that enhances the viral transduction of the urothelium, leading to production of IFN-α2b protein.”
> “Cystectomy-free survival at month 60 was 49% (43% in the CIS cohort and 59% in the Ta/T1 cohort)”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.3-2"></a>

### Nadofaragene firadenovec: labeled indication

> “ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-3"></a>

### Nadofaragene firadenovec: dosing and administration

> “Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN.”
> “After the instillation, ADSTILADRIN should be retained in the bladder for 1 hour. During the 1-hour dwell time, the patient should reposition approximately every 15 minutes from left to right, back and abdomen to maximize bladder surface exposure.”
> “Voided urine should be disinfected for 15 minutes with an equal volume of virucidal agent before flushing of the toilet.”
> “ADSTILADRIN is provided in a carton containing four (4) vials.”
> “ADSTILADRIN is shipped frozen at ≤ -60°C (≤ -76°F) in an insulated shipping box that will maintain the required temperature for a minimum of 72 hours after being sealed.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-4"></a>

### Nadofaragene firadenovec: efficacy in the pivotal trial (label)

> “The efficacy of ADSTILADRIN was evaluated in CS-003 (NCT02773849), an open-label, multicenter, single-arm trial in 103 adults with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors following transurethral resection, of whom 98 were considered evaluable for response.”
> “The major efficacy outcome measures were complete response (CR) at any time (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable] and urine cytology) and duration of response.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

| Efficacy outcome measure (Study CS-003) | Adstiladrin (n=98) |
| --- | --- |
| Complete response rate | “51%” |
| 95% CI | “(41%, 61%)” |
| Median duration of response in months (range) | “9.7 (3, 52+)” |
| Duration of response ≥ 12 months | “46%” |

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-5"></a>

### Nadofaragene firadenovec: phase 3 trial results by cohort

> “55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.”
> “In the high-grade Ta or T1 cohort, 35 of 48 patients (72·9%; 95% CI 58·2 to 84·7) were high-grade recurrence-free at month 3, and 21 patients (43·8%; 29·5 to 58·8) were recurrence-free at month 12.”

Source: [Boorjian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7988888/)

<a id="topic-2.2.2.1.3-6"></a>

### Nadofaragene firadenovec: 5-year follow-up of the phase 3 trial

> “Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months.”
> “Kaplan-Meier–estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively.”
> “Most adverse events were grades 1 or 2 (66%), with 3.8% of patients reporting grade 3 events and no patients experiencing grades 4 or 5 study-drug related adverse events.”

Source: [Narayan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721637/)

<a id="topic-2.2.2.1.3-7"></a>

### Nadofaragene firadenovec: FDA approval summary

> “On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).”
> “Fifty subjects experienced CR 3 months after initial treatment (CR=51%; 95% CI: 40.7; 61.3%), of whom 46% remained in response for ≥12 months. The median DoR was 9.7 months (range: 3 to 52+).”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

<a id="topic-2.2.2.1.3-8"></a>

### Nadofaragene firadenovec: adverse reactions in the pivotal trial

> “Serious adverse reactions occurred in 11% of patients who received ADSTILADRIN.”
> “Permanent discontinuation of ADSTILADRIN due to an adverse reaction occurred in 3 (1.9%) patients.”
> “Dosage interruptions of ADSTILADRIN due to an adverse reaction occurred in 54 (34%) patients.”
> “The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination) urgency, creatinine increased, hematuria (blood in urine), phosphate decreased, chills, dysuria, and pyrexia (fever).”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-9"></a>

### Nadofaragene firadenovec: warnings on delayed cystectomy and disseminated adenovirus infection

> “Of the patients with CIS treated with ADSTILADRIN on Study CS-003 who underwent subsequent radical cystectomy and for whom pathologic data were available, 14% (n = 6) had muscle-invasive (T2 or greater) disease at cystectomy.”
> “If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.”
> “Immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection because of the possible presence of low levels of replication-competent adenovirus in ADSTILADRIN.”

Source: [Adstiladrin prescribing information (2026)](https://www.fda.gov/media/164029/download)

<a id="topic-2.2.2.1.3-10"></a>

### Nadofaragene firadenovec: real-world outcomes at a multisite academic center

> “Of 24 evaluable patients with carcinoma in situ with/without papillary disease, 79% had a CR at 3 months. The median response duration was not reached; 68% (13/19) of responders still had CRs with median follow-up of 9.3 months. Of 19 patients with papillary-only disease (median follow-up of 7.6 months), HGRFS at 3, 6, and 12 months was 68%, 53%, and 26%, respectively.”
> “The most common adverse events were grade 1–2 bladder spasms (61%) and failure to fully retain the instillation (33%).”

Source: [Moyer et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721500/)

<a id="topic-2.2.2.1.3-11"></a>

### Detalimogene voraplasmid: investigational non-viral gene therapy, LEGEND pivotal Cohort 1

> “Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease.”
> “The following efficacy data are based on 120 efficacy-evaluable patients enrolled in Cohort 1 as of the data cutoff date, October 29, 2026.”
> “CR at any time of 56% (CI:47%, 65%) (n=120)”
> “Landmark 12-month CR rate is 24% (CI: 16%, 33%) (n=110)”
> “Median duration of complete response is 10.1 months (CI: 7.5, Not Estimable)”
> “Of the 125 patients assessed for safety in Cohort 1, 59% experienced at least one TRAE, which were mainly Grade 1/2 in severity.”
> “Only 4% of patients experienced Grade 3 TRAE, with just 2% of patients experiencing a serious TRAE. No Grade 4 or Grade 5 TRAEs were reported.”
> “The Company expects to initiate the submission by year-end 2026 and plans to complete the BLA submission in the first half of 2027, with potential FDA approval in 2027.”

Source: [enGene LEGEND Cohort 1 and BLA plan press release (2026)](https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx)

<a id="topic-2.2.2.1.3-12"></a>

### Detalimogene voraplasmid: LEGEND phase 2 dosing regimen

> “Under the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles, of EG-70 at the RP2D defined in Phase 1, administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.”

Source: [ClinicalTrials.gov NCT04752722](https://clinicaltrials.gov/study/NCT04752722)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
